Nordic Nanovector ASA (OSE: NANO) is pleased to announce that Lisa Rojkjaer, MD has joined the company today as Chief Medical Officer (CMO) and as a member of the Executive Management Team. Dr Rojkjaer will lead all clinical development strategy and execution and support the company’s efforts to identify opportunities to expand its pipeline of […]
https://radforsk.no/wp-content/uploads/2016/11/NordicNanovector-1.png4301500radforskhttp://radforsk.no/wp-content/uploads/2017/09/rf_logo.pngradforsk2016-11-16 11:57:462019-01-17 08:51:21Nordic Nanovector appoints Dr Lisa Rojkjaer, MD as Chief Medical Officer
The Norwegian Research Council granted Oslo Cancer Cluster member companies Oncoimmunity, Vaccibody, Nextera and Nordic Nanovector funding through the Programme for User-Driven Research Based Innovation (BIA). In total, the Norwegian Research Council will grant 532 MNOK to 50 Norwegian companies, of which 10 are within biomedicine. Oncoimmunity, Vaccibody, Nextera and Nordic Nanovector will receive between […]
Nordic Nanovector appoints Dr Lisa Rojkjaer, MD as Chief Medical Officer
/in Portfolio Companies /by radforskNordic Nanovector ASA (OSE: NANO) is pleased to announce that Lisa Rojkjaer, MD has joined the company today as Chief Medical Officer (CMO) and as a member of the Executive Management Team. Dr Rojkjaer will lead all clinical development strategy and execution and support the company’s efforts to identify opportunities to expand its pipeline of […]
Photocure ASA: Third Quarter 2016
/in Portfolio Companies /by radforskPhotocure delivers strong third quarter results.
Oncoimmunity, Vaccibody, Nextera and Nordic Nanovector granted BIA-funding
/in Portfolio Companies /by radforskThe Norwegian Research Council granted Oslo Cancer Cluster member companies Oncoimmunity, Vaccibody, Nextera and Nordic Nanovector funding through the Programme for User-Driven Research Based Innovation (BIA). In total, the Norwegian Research Council will grant 532 MNOK to 50 Norwegian companies, of which 10 are within biomedicine. Oncoimmunity, Vaccibody, Nextera and Nordic Nanovector will receive between […]